@RheumNow video from #ACR22 Opioid use in PsA and SpA patients Discussing abstract 1012 by @AlexisOgdie https://t.co/fKRog1aIkH

Jones et al. Non-smokers, normal BMI, and current drinkers! with AxSpA more likely to respond to TNFi. @RheumNow #ACR22 Abstr#1510 https://t.co/inCz2sAyj5 https://t.co/K27ptuLV7Y

• Modifying Lifestyle Factors May Offer the Potential to Enhance the Outcome of T…

#ClinicalPearl woman with non-radiographic axSpA have LESS inactive disease vs MEN but NOT true if radiographic axSpA. 5 yr global study N=2633, independent of TNFi use - not sure why there are differences. Misclassification dx- unlikely. abst#1614 #ACR22 #ACRBest @RheumNowNews https://t.co/coNjwHOkLP

Kiltz et al. Greater efficacy of secukinumab in normal BMI than high BMI AS patients. Decremental effect with increasing BMI. @RheumNow #ACR22 Abstr#1495 https://t.co/zwEmQsJmPT https://t.co/nOW2IbTc5t

• How Does Body Mass Index Affect Secukinumab Treatment Outcomes and Safety in Pa…

Benesova et al. Higher treatment response to secukinumab in both male and female AS patients when diagnosed earlier. No such effect seen in PsA patients. Emphasises need to reduce diagnostic delay in AS. @RheumNow #ACR22 Abstr#1497 https://t.co/9g2zN85a33 https://t.co/LfvQFTKr69

• How Does Time to Diagnosis and Gender Affect Treatment Outcomes in Patients wit…

Torgutalp et al. Higher NSAID intake associated reduced spinal progression in AxSpA esp. r-AxSpA. Cox-2 may have greater effect than other NSAIDs. @RheumNow #ACR22 Abstr#1492 https://t.co/bGH6bBo7AD https://t.co/XBFV410Y2p

• Treatment with Non-steroidal Anti-inflammatory Drugs Is Associated with Retarda…

CorEVITAS Abs 1499 #ACRbest #ACR22 cycling to a second line TNFi provides limited benefits to pts with AxSpA who discontinued a first line TNFi. @RheumNow https://t.co/fKDa5kPfXN https://t.co/CtMCj2Ihgc

• The Impact of Cycling Among Tumor Necrosis Factor Inhibitors on Disease Control…

Papagoras et al. Serum GM-CSF increased in AxSpA and persists despite TNFi. Are we going to have a trial of mavrilimumab in AxSpA then? @RheumNow #ACR22 Abstr#1156 https://t.co/wCFsY9nC1p https://t.co/lrQQ7tIX4x

• Serum Granulocyte-Macrophage Colony Stimulating Factor (GM-CSF) Is Increased in…

Delay in AS dx appeared to be BMI-dependent in female pts and both genders n PsA dx. In contrast to AS, SEC treatment response of early- and late-diagnosed PsA pts did not differ. Abs 1497 #ACR22 @RheumNow https://t.co/LBo3XapAT4 https://t.co/uAcfeiED4F

• How Does Time to Diagnosis and Gender Affect Treatment Outcomes in Patients wit…

Lower socioeconomic status (cluster 1) patients: ● older age at the diagnosis (37.9 vs. 32.6) ● longer diagnosis delay (7.8 vs. 6.8 years) ● higher BMI (27.6 vs. 25.9) ● greater structural damage vs cluster 2 Lopez-Medina C Abs0376 https://t.co/wXOksFGDKl #ACR22 @RheumNow https://t.co/1YVRA6r1sw

• The Socioeconomic Profile of Patients with Radiographic Axial Spondyloarthritis…

Patients with PsA and AS who used opioids had higher healthcare utilization and higher costs. Also ➣ more comorbidities ➣ higher prevalence of smoking ➣ worse disease activity ➣ higher use of anti-rheumatic drugs Ogdie A Abs0402 https://t.co/3E4qAuqgpI #ACR22 @RheumNow https://t.co/AaKxiQXMwx

• Opioid Use and Healthcare Utilization in Adults with PsA and AS - ACR Meeting A…

Lifestyle modifications can affect tx response with TNFi in axSpA! Accdg to this study fr Prof GJones, ✳️Smokers, overwt & obese pts are ⬇️ likely to achieve treatment response to TNFi vs. nonsmokers & normal wt pts Smoking cessation, wt mgt is key! #ACR22 @RheumNow ABST#1510 https://t.co/PBFcj6zKVD